Skip to main content

Table 1 Patient characteristics

From: Impact of double J stenting or nephrostomy placement during transurethral resection of bladder tumour on the incidence of metachronous upper urinary tract urothelial cancer

Parameter

Total n = 637

Gender

 male

79.4% (506/637)

 female

20.6% (131/637)

Age at initial diagnosis BCa (mean ± SD; years)

72.5 ± 11.5

T stage BCa at initial diagnosis

 pTa

41.8% (266/637)

 pT1

30.0% (191/637)

 pT2

26.7% (170/637)

 pT3

0.3% (2/637)

 pT4

0.2% (1/637)

 pTis

0.5% (3/637)

 PUNLMP

0.5% (3/637)

 unknown

0.2% (1/637)

Concomitant CIS at initial diagnosis

 yes

7.5% (48/637)

 no

92.5% (589/637)

Grading (WHO 1973) BCa at initial diagnosis

 G1

18.7% (119/637)

 G2

44.4% (283/637)

 G3

36.6% (233/637)

 unknown

0.3% (2/637)

Grading (WHO 2004) BCa at initial diagnosis

 low-grade

20.4% (130/637)

 high-grade

74.9% (477/637)

 unknown

4.7% (30/637)

Hydronephrosis

 no

86.8% (553/637)

 left

3.8% (24/637)

 right

4.6% (29/637)

 bilateral

4.9% (31/637)

Urinary drainage of the upper urinary tract

 no

80.8% (515/637)

 DJ

11.6% (74/637)

 percutaneous nephrostomy

5.7% (36/637)

 percutaneous nephrostomy for anterograde DJ

1.6% (10/637)

 percutaneous nephrostomy and DJ

0.3% (2/637)

Upper urinary tract urothelial carcinoma (UUTUC)

 no

95.6% (609/637)

 yes

4.4% (28/637)

  UUTUC prior to BCa

39.3% (11/28)

  UUTUC synchronous to BCa

32.1% (9/28)

  UUTUC metachronous to BCa

28.6% (8/28)

Death

 no

87.9% (560/637)

 yes

12.1% (77/637)

  1. BCa bladder cancer, CIS carcinoma in situ, DJ double J stent, PUNLMP papillary urothelial neoplasm of low malignant potential, SD standard deviation, UUTUC upper urinary tract urothelial cancer, WHO World Health Organization